Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ALT Altimmune Inc
- Stocks
- Healthcare
- NASDAQ: ALT
Price (delayed)
$5.7
Market cap
$462.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.26
Enterprise value
$413.16M
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™),
Highlights
Altimmune's EPS has increased by 22% YoY and by 6% QoQ
Altimmune's net income has increased by 5% QoQ and by 2.7% YoY
ALT's quick ratio is up by 21% QoQ but it is down by 4.6% YoY
The equity has declined by 18% year-on-year but it has increased by 15% since the previous quarter
ALT's revenue has dropped by 96% year-on-year and by 25% since the previous quarter
The gross profit has plunged by 96% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of ALT
Market
Valuations
Earnings
Shares outstanding
81.11M
Market cap
$462.31M
Enterprise value
$413.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.09
Price to sales (P/S)
28,708.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27,544.25
Revenue
$15,000
Gross profit
$15,000
Operating income
-$98.2M
Net income
-$90.24M
EBIT
-$90.91M
EBITDA
-$90.75M
Free cash flow
-$80.33M
Per share
Balance sheet
Liquidity
EPS
-$1.26
EPS diluted
-$1.26
Free cash flow per share
-$1.06
Book value per share
$1.85
Revenue per share
$0
TBVPS
$2.08
Total assets
$157.26M
Total liabilities
$15.1M
Debt
$0
Equity
$142.16M
Working capital
$145.46M
Debt to equity
0
Current ratio
15.85
Quick ratio
15.35
Net debt/EBITDA
0.54
Margins
Efficiency
Dividend
EBITDA margin
-605,013.3%
Gross margin
100%
Net margin
-601,600%
Operating margin
-654,653.3%
Return on assets
-58.4%
Return on equity
-65.4%
Return on invested capital
-91.2%
Return on capital employed
-61.6%
Return on sales
-606,080%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALT stock price
How has the Altimmune stock price performed over time
Intraday
-1.04%
1 week
6.34%
1 month
23.11%
1 year
-27.11%
YTD
-20.94%
QTD
14%
Financial performance
How have Altimmune's revenue and profit performed over time
Revenue
$15,000
Gross profit
$15,000
Operating income
-$98.2M
Net income
-$90.24M
Gross margin
100%
Net margin
-601,600%
ALT's revenue has dropped by 96% year-on-year and by 25% since the previous quarter
The gross profit has plunged by 96% YoY and by 25% from the previous quarter
The net margin has declined by 27% since the previous quarter
The operating margin has declined by 27% since the previous quarter
Price vs fundamentals
How does ALT's price correlate with its fundamentals
Growth
What is Altimmune's growth rate over time
Valuation
What is Altimmune stock price valuation
P/E
N/A
P/B
3.09
P/S
28,708.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27,544.25
Altimmune's EPS has increased by 22% YoY and by 6% QoQ
The P/B is 29% higher than the 5-year quarterly average of 2.4 but 6% lower than the last 4 quarters average of 3.3
The equity has declined by 18% year-on-year but it has increased by 15% since the previous quarter
ALT's revenue has dropped by 96% year-on-year and by 25% since the previous quarter
ALT's P/S is 88% above its last 4 quarters average of 15308.3
Efficiency
How efficient is Altimmune business performance
The company's return on invested capital rose by 33% YoY and by 4.4% QoQ
Altimmune's return on sales has decreased by 28% QoQ
The return on equity has declined by 21% year-on-year
ALT's ROA is down by 18% YoY
Dividends
What is ALT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Altimmune financials performed over time
ALT's quick ratio is up by 21% QoQ but it is down by 4.6% YoY
Altimmune's current ratio has increased by 21% from the previous quarter but it has decreased by 4.2% YoY
The debt is 100% smaller than the equity
The equity has declined by 18% year-on-year but it has increased by 15% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.